GMP Vector Manufacturing Facility for Tissue Engineering
- Client
- I'rom Group Co., Ltd./ID Pharma Co., Ltd.
- Location
- Tsukuba, Ibaraki, Japan
- Scope of Work
- Engineering, Procurement, Construction and Validation (E.P.C.V)
- Year of completion
- 2016
The World’s first GMP Compliant Vector Manufacturing Plant with “Sendai Virus Vector”
Chiyoda executed the Engineering, Procurement, Construction and Validation (EPCV) work for the facility to manufacture clinical use vector* for regenerative medicine and genomic drug discovery for I’ROM Group Co., Ltd./ID Pharma Co., Ltd..
In the field of regenerative medicine such as development of iPS cell in the field of genomic drug discovery such as gene therapy and gene vaccine drug, this project is to construct the world’s first GMP compliant vector manufacturing plant including “Sendai Virus Vector” based upon the technology of ID Pharma Co., Ltd., a wholly owned subsidiary of I’ROM Group Co., Ltd.
- Vector is a material that delivers curative gene to the specific organ/anatomy and imports the gene into the targeted cell effectively. “Sendai Virus Vector” which is uniquely developed by ID Pharma Co., Ltd. is RNA based Vector, completely different from the existing vector technology. Sendai Virus Vector is verified safe through preclinical testing, and has high reliability and track record in the field of gene-drug and bio-drug.
